About this journal
Aims and scope
Amyloid is the official journal of the International Society of Amyloidosis.
Amyloid publishes basic and clinical research on amyloids and systemic and localized amyloidosis.The journal's scope and major areas of focus are:
- Etiology
- Epidemiology
- Genetics
- Pathogenesis, including chemical structure, fibrillogenesis and mechanism of disease
- Pathology
- Diagnosis, treatment and prognosis across a broad spectrum of clinical specialties impacted by various amyloid diseases and related disorders.
The journal publishes research articles, letters to the Editor, review articles (typically by invitation), and editorials.
Authors can choose to publish gold open access in this journal.
Journal metrics
Usage
- 125K annual downloads/views
Citation metrics
- 5.2 (2023) Impact Factor
- Q1 Impact Factor Best Quartile
- 6.7 (2023) 5 year IF
- 10.6 (2023) CiteScore (Scopus)
- Q1 CiteScore Best Quartile
- 1.939 (2023) SNIP
- 2.007 (2023) SJR
Speed/acceptance
- 20 days avg. from submission to first decision
- 46 days avg. from submission to first post-review decision
- 20% acceptance rate
Understanding and using journal metrics
Journal metrics can be a useful tool for readers, as well as for authors who are deciding where to submit their next manuscript for publication. However, any one metric only tells a part of the story of a journal’s quality and impact. Each metric has its limitations which means that it should never be considered in isolation, and metrics should be used to support and not replace qualitative review.
We strongly recommend that you always use a number of metrics, alongside other qualitative factors such as a journal’s aims & scope, its readership, and a review of past content published in the journal. In addition, a single article should always be assessed on its own merits and never based on the metrics of the journal it was published in.
For more details, please read the Author Services guide to understanding journal metrics.
Journal metrics in brief
Usage and acceptance rate data above are for the last full calendar year and are updated annually in February. Speed data is updated every six months, based on the prior six months. Citation metrics are updated annually mid-year. Please note that some journals do not display all of the following metrics (find out why).
- Usage: the total number of times articles in the journal were viewed by users of Taylor & Francis Online in the previous calendar year, rounded to the nearest thousand.
Citation Metrics
- Impact Factor*: the average number of citations received by articles published in the journal within a two-year window. Only journals in the Clarivate Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI), Arts and Humanities Citation Index (AHCI) and the Emerging Sources Citation Index (ESCI) have an Impact Factor.
- Impact Factor Best Quartile*: the journal’s highest subject category ranking in the Journal Citation Reports. Q1 = 25% of journals with the highest Impact Factors.
- 5 Year Impact Factor*: the average number of citations received by articles in the journal within a five-year window.
- CiteScore (Scopus)†: the average number of citations received by articles in the journal over a four-year period.
- CiteScore Best Quartile†: the journal’s highest CiteScore ranking in a Scopus subject category. Q1 = 25% of journals with the highest CiteScores.
- SNIP (Source Normalized Impact per Paper): the number of citations per paper in the journal, divided by citation potential in the field.
- SJR (Scimago Journal Rank): Average number of (weighted) citations in one year, divided by the number of articles published in the journal in the previous three years.
Speed/acceptance
- From submission to first decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision. Based on manuscripts receiving a first decision in the last six months.
- From submission to first post-review decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision if it is sent out for peer review. Based on manuscripts receiving a post-review first decision in the last six months.
- From acceptance to online publication: the average (median) number of days from acceptance of a manuscript to online publication of the Version of Record. Based on articles published in the last six months.
- Acceptance rate: articles accepted for publication by the journal in the previous calendar year as percentage of all papers receiving a final decision.
For more details on the data above, please read the Author Services guide to understanding journal metrics.
*Copyright: Journal Citation Reports®, Clarivate Analytics
†Copyright: CiteScore™, Scopus
Editorial board
Prof Per Westermark - Uppsala University, Uppsala, Sweden
Associate Editors:
Angela Dispenzieri - Mayo Clinic, USA
Mathew S. Maurer - Columbia University, USA
Giampaolo Merlini - Amyloidosis Research and Treatment Center, Italy
Vaishali Sanchorawala - Boston University School of Medicine, USA
Stefan Schönland - University Hospital of Heidelberg, Germany
Yoshiki Sekijima - Shinshu University School of Medicine, Japan
Editorial Board:
David Adams - France
Kevin M. Alexander - USA
Intissar Anan - Sweden
Yukio Ando - Japan
Gunnar Antoni - Sweden
Vittorio Bellotti - Italy
John L. Berk - USA
Joel N. Buxbaum - USA
Fabrizio Chiti - Italy
Teresa Coelho - Portugal
Isabel Conceicao - Portugal
Thibaud Damy - France
Noel Dasgupta - USA
Sharmila Dorbala - USA
David S. Eisenberg - USA
Michele Emdin - Italy
Rodney H. Falk - USA
Marcus Fändrich - Germany
Pablo Garcia-Pavia - Spain
Ehud Gazit - Israel
Morie A. Gertz - USA
Justin L. Grodin - USA
Per Hammarström - Sweden
Philip N. Hawkins - UK
Bouke P.C. Hazenberg - Netherlands
Ute Hegenbart - Germany
Keiichi Higuchi - Japan
Arnaud Jaccard - France
Daniel P. Judge - USA
Astrid Juhl Terkelsen - Denmark
Aphrodite Kapurniotu - Germany
Efstathios Kastritis - Greece
Jeffrey W. Kelly - USA
Hiroaki Kitaoka - Japan
Haruki Koike - Japan
Arnt Kristen - Germany
Shaji Kumar - USA
Francesca Lavatelli Italy
Ahmed Masri - USA
Ellen D. McPhail - USA
Paolo Milani - Italy
Peter Mollee - Australia
Eli Muchtar - USA
Tomoaki Murakami - Japan
Hironobu Naiki - Japan
Tahara Nobuhiro - Japan
Mario Nuvolone - Italy
Laura Obici - Italy
Giovanni Palladini - Italy
Federico Perfetto - Italy
Stefano Perlini - Italy
Maria M. Picken - USA
Violaine Plante-Bordeneuve - France
Stanley B. Prusiner - USA
Sheena E. Radford - UK
Marina Ramirez-Alvarado - USA
Chris Röcken - Germany
Julie L. Rosenthal - USA
Frederick L. Ruberg - USA
Maria M. Saraiva - Portugal
Elisabeth Sauer-Eriksson - Sweden
Dennis J. Selkoe - USA
Louise Serpell - UK
Prem Soman - USA
Mitsuharu Ueda - Japan
Márcia Waddington Cruz - Brazil
Jonathan S. Wall - USA
Ashutosh Wechalekar - UK
Gunilla T. Westermark - Sweden
Jonas Wixner - Sweden
Abstracting and indexing
Amyloid: The Journal of Protein Folding Disorders is indexed/tracked/covered by the following services:
BIOSIS Previews (Clarivate Analytics)
Current Contents - Life Sciences (Clarivate Analytics)
Current Awareness in Biological Sciences
Embase (Elsevier)
Index Medicus (NLM)
ISI Research Alert
Medline (NLM)
PubMed (NLM)
PubMed Central Selective Deposit Medicine & Health (NLM)
Science Citation Index (Clarivate Analytics)
Science Citation Index Expanded (Clarivate Analytics)
Scopus (Elsevier)
Open access
Amyloid is a hybrid open access journal that is part of our Open Select publishing program, giving you the option to publish open access. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research.
Why choose open access?
- Increase the discoverability and readership of your article
- Make an impact and reach new readers, not just those with easy access to a research library
- Freely share your work with anyone, anywhere
- Comply with funding mandates and meet the requirements of your institution, employer or funder
- Rigorous peer review for every open access article
Article Publishing Charges (APC)
If you choose to publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis.
Use our APC finder to calculate your article publishing charge
4 issues per year
Advertising information
Would you like to advertise in Amyloid?
Reach an engaged target audience and position your brand alongside authoritative peer-reviewed research by advertising in Amyloid.
Taylor & Francis make every effort to ensure the accuracy of all the information (the "Content") contained in our publications. However, Taylor & Francis, our agents (including the editor, any member of the editorial team or editorial board, and any guest editors), and our licensors, make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to, or arising out of the use of the Content. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions .
Ready to submit?
Start a new submission or continue a submission in progress
Go to submission site (link opens in a new window) Instructions for authors